David Abrams Buys 3, Sells 2 in 2nd Quarter

Author's Avatar
insider
Aug 12, 2022
Article's Main Image

David Abrams recently filed their 13F report for the second quarter of 2022, which ended on 2022-06-30.

The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.

David Abrams (Trades, Portfolio) founded Abrams Capital Management in 1999, where he is the CEO and portfolio manager. Before establishing the Boston-based firm, he worked with Baupost’s

Seth Klarman (Trades, Portfolio) for 10 years.

As of the latest 13F report, the guru’s equity portfolio contained 18 stocks valued at a total of $3.72Bil. The top holdings were LAD(17.37%), CHNG(10.52%), and ABG(9.64%).

According to GuruFocus data, these were

David Abrams (Trades, Portfolio)’s top five trades of the quarter.

Coupang Inc


During the quarter,

David Abrams (Trades, Portfolio) bought 3,908,261 shares of NYSE:CPNG for a total holding of 13,603,071. The trade had a 1.61% impact on the equity portfolio. During the quarter, the stock traded for an average price of $21.39.

On 08/12/2022, Coupang Inc traded for a price of $18.87 per share and a market cap of $33.26Bil. The stock has returned -44.71% over the past year.

GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 1 out of 10.

In terms of valuation, Coupang Inc has a price-book ratio of 16.35, a EV-to-Ebitda ratio of -27.11 and a price-sales ratio of 1.69.

Nuvation Bio Inc


The guru sold out of their 3,811,513-share investment in NYSE:NUVB. Previously, the stock had a 0.71% weight in the equity portfolio. Shares traded for an average price of $5.86 during the quarter.

On 08/12/2022, Nuvation Bio Inc traded for a price of $5.445 per share and a market cap of $1.19Bil. The stock has returned -49.55% over the past year.

There is insufficient data to calculate the stock’s financial strength and profitability ratings.

In terms of valuation, Nuvation Bio Inc has a price-book ratio of 1.58 and a EV-to-Ebitda ratio of -12.19.

Nuvation Bio Inc


The guru established a new position worth 3,811,513 shares in NYSE:NUVB, giving the stock a 0.47% weight in the equity portfolio. Shares traded for an average price of $5.17 during the quarter.

On 08/12/2022, Nuvation Bio Inc traded for a price of $2.88 per share and a market cap of $628.54Mil. The stock has returned 0.00% over the past year.

GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 2 out of 10.

In terms of valuation, Nuvation Bio Inc has a price-book ratio of 0.89 and a EV-to-Ebitda ratio of 0.82.

Amerco Inc


David Abrams (Trades, Portfolio) reduced their investment in NAS:UHAL by 25,061 shares. The trade had a 0.4% impact on the equity portfolio. During the quarter, the stock traded for an average price of $616.93.

On 08/12/2022, Amerco Inc traded for a price of $569.23 per share and a market cap of $11.16Bil. The stock has returned -13.09% over the past year.

GuruFocus gives the company a financial strength rating of 5 out of 10 and a profitability rating of 10 out of 10.

In terms of valuation, Amerco Inc has a price-earnings ratio of 10.04, a price-book ratio of 1.85, a price-earnings-to-growth (PEG) ratio of 0.86, a EV-to-Ebitda ratio of 6.14 and a price-sales ratio of 1.91.

The price-to-GF Value ratio is 0.96, earning the stock a GF Value rank of 7.

Cantaloupe Inc


During the quarter,

David Abrams (Trades, Portfolio) bought 1,000,000 shares of NAS:CTLP for a total holding of 3,090,000. The trade had a 0.16% impact on the equity portfolio. During the quarter, the stock traded for an average price of $7.6.

On 08/12/2022, Cantaloupe Inc traded for a price of $6.68 per share and a market cap of $475.02Mil. The stock has returned -33.00% over the past year.

GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 3 out of 10.

In terms of valuation, Cantaloupe Inc has a price-earnings ratio of 167.00, a price-book ratio of 3.01, a EV-to-Ebitda ratio of 49.76 and a price-sales ratio of 2.42.

The price-to-GF Value ratio is 0.73, earning the stock a GF Value rank of 8.


Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.

Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!

This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.

Also check out:
    Rating:
    0 / 5 (0 votes)
    Author's Avatar
    WRITTEN BY

    Request A Demo

    Learn more about GuruFocus' key features, including All-In-One Screener, backtesting, 30-year financial, stock summary page, guru trades, insider trades, excel Add-in, google sheets and much more.

    GuruFocus Screeners

    Related Articles